Why the study?
Do patients with type II and type IV hyperlipidemia have altered platelet sensitivity to prostacyclin and thromboxane production compared to healthy controls?
Population
46 individuals: 13 type II hyperlipidemics, 10 type IV hyperlipidemics, and 23 healthy age- and sex-matched…
Design
Case-control
Authors
Loading...
May explain heightened thrombotic risk in type II hyperlipidemia; leaves open whether targeting these platelet changes improves outcomes.
Do patients with type II and type IV hyperlipidemia have altered platelet sensitivity to prostacyclin and thromboxane production compared to healthy controls?
Type II hyperlipidemia is associated with reduced platelet sensitivity to prostacyclin and increased thromboxane production, providing a potential mechanism for the increased platelet aggregation observed in these patients.
Strano et al. (1982) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: